Experience

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 6,500,000 shares of common stock of Applied Genetic Technologies…

Davis Polk advised the underwriters in connection with a $75 million public offering of common stock by RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on the …

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the initial purchasers on a Rule 144A offering by Integra LifeSciences Holdings Corporation of $575 million…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $281.75 million initial public offering by 1Life Healthcare, Inc…

Davis Polk advised the underwriters in connection with Alector, Inc.’s $240 million public offering of 9,602,500 shares of common stock, which includes the 1,252,500 shares offered pursuant…

Davis Polk advised the joint book-running managers in connection with an initial public offering of 10,586,316 shares of common stock of Black Diamond Therapeutics, Inc. In addition,…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $207 million public offering of common stock of Denali Therapeutics,…

Davis Polk advised Zai Lab Limited in connection with its follow-on offering of approximately $300 million of American depositary shares, representing 5,500,000 ordinary shares by the…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 3,152,712 shares of common stock of Applied Therapeutics, Inc., including 411,223 shares of common…